PRLD (STOCKS)
Prelude Therapeutics Incorporated
$4.400000
+0.320000 (+7.84%)
Prev close: $4.080000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Krishna Vaddi
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $275.32M
- Employees
- 131
- P/E (TTM)
- -3.23
- P/B (TTM)
- 3.74
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.20 | $-0.03 | -0.1704 | -575.68% |
|
Sep 2025 (Q3)
|
$-0.26 | $-0.37 | +0.1126 | +30.22% |
|
Jun 2025 (Q2)
|
$-0.41 | $-0.45 | +0.0383 | +8.54% |
|
Mar 2025 (Q1)
|
$-0.42 | $-0.48 | +0.0577 | +12.08% |
Financial Statements
| Revenues | $12.14M |
| Benefits Costs and Expenses | $111.64M |
| Costs And Expenses | $111.64M |
| Operating Expenses | $116.71M |
| Research and Development | $94.30M |
| Other Operating Expenses | $22.41M |
| Operating Income/Loss | -$104.57M |
| Income/Loss From Continuing Operations After Tax | -$99.50M |
| Income/Loss From Continuing Operations Before Tax | -$99.50M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$99.50M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$99.50M |
| Net Income/Loss Available To Common Stockholders, Basic | -$99.50M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.29 |
| Diluted Earnings Per Share | -$1.29 |
| Basic Average Shares | 76,956,194 |
| Diluted Average Shares | 76,956,194 |
| Assets | $141.32M |
| Current Assets | $105.69M |
| Noncurrent Assets | $35.62M |
| Fixed Assets | $5.11M |
| Other Non-current Assets | $30.51M |
| Liabilities | $72.68M |
| Current Liabilities | $52.99M |
| Accounts Payable | $3.98M |
| Wages | $7.14M |
| Other Current Liabilities | $41.87M |
| Noncurrent Liabilities | $19.68M |
| Equity | $68.64M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $68.64M |
| Liabilities And Equity | $141.32M |
| Net Cash Flow From Operating Activities | -$56.30M |
| Net Cash Flow From Operating Activities, Continuing | -$56.30M |
| Net Cash Flow From Investing Activities | $53.46M |
| Net Cash Flow From Investing Activities, Continuing | $53.46M |
| Net Cash Flow From Financing Activities | $24.82M |
| Net Cash Flow From Financing Activities, Continuing | $24.82M |
| Net Cash Flow | $21.97M |
| Net Cash Flow, Continuing | $21.97M |
| Comprehensive Income/Loss | -$99.53M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$99.53M |
| Other Comprehensive Income/Loss | -$27.00K |